In this Issue:
COMBI-v trial: health-related quality of life
Acute skin reaction suggestive of pembrolizumab-induced radiosensitisation
Advanced BRAF V600-mutant melanoma and BRAF inhibitor rechallenge
Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma
Regression in primary melanoma and sentinel lymph node status
Immune-related adverse events in patients with melanoma treated with ipilimumab
Nicotinamide for skin-cancer chemoprevention
Isolated limb perfusion in melanoma patients with recurrent in-transit metastases
Incidence of and risk factors associated with multiple primary melanomas
Cutaneous toxic effects of BRAF inhibitor monotherapy and CombiDT therapy
Please login below to download this issue (PDF)